查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613020

全球叢集性頭痛市場（按叢集性頭痛類型、藥物類型、給藥途徑和分銷管道）：未來預測（2025-2030）

Cluster Headache Market by Cluster Headaches Type, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，叢集性頭痛市場價值為3.8104億美元，預計到2024年將達到4.018億美元，複合年成長率為5.71%，到2030年將達到5.6238億美元。

叢集性頭痛是一種神經系統疾病，其特徵是頭部一側（通常是眼睛周圍）反覆發作劇烈疼痛。叢集性頭痛的研究和市場分析範圍包括了解有效治療的需求、醫療實踐中的應用以及主要包括製藥公司、醫療保健提供者和患者的最終用途範圍。這種疾病的盛行率不斷上升及其對患者生活品質的破壞性影響推動了對治療解決方案的需求。影響市場成長的主要因素包括神經學研究的進步、意識的提高以及醫療基礎設施的改善。在正在進行的臨床試驗和監管核准的推動下，非侵入性神經刺激療法和新穎配方等創新療法正在提供新的商機。然而，新治療方法的高成本、新興市場的患者獲取機會有限以及準確診斷這種罕見疾病的複雜性等挑戰構成了巨大的市場障礙。為了利用潛在的機會，相關人員應專注於與生物技術公司和研究機構合作，加速研究和開發，投資於公眾意識宣傳活動，並透過學名藥開發提高可及性。此外，透過集中精力進行個人化醫療和尋找與叢集性頭痛相關的遺傳傾向，可以發現開拓的市場潛力。雖然技術創新目前集中在標靶藥物療法和技術整合上，但對生活方式改變和綜合療法等非藥物干預措施的更深入探索有可能使治療管道多樣化。競爭格局仍適度集中，GlaxoSmithKline Plc等大型製藥企業與新興生技公司競爭。最終，在未滿足的臨床需求和不斷發展的治療範式的推動下，未滿足的關鍵字市場將會成長，但必須克服經濟和教育方面的限制，以實現公平的市場擴張。

主要市場統計
基準年[2023] 38104萬美元
預計年份 [2024] 4.018 億美元
預測年份 [2030] 56238萬美元
複合年成長率（%） 5.71%

市場動態：揭示快速發展的叢集性頭痛市場的關鍵市場洞察

供需的動態交互作用正在改變叢集性頭痛市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球叢集性頭痛盛行率上升
    • 藥品和醫療技術領域的持續研究和開發舉措
    • 醫療投入快速增加擴大治療選擇
  • 市場限制因素
    • 對叢集性頭痛缺乏認知或誤診
  • 市場機會
    • 針對每位患者基因量身定做的個人化醫療的進展
    • 新開發的叢集性頭痛藥物繼續產品核可
  • 市場挑戰
    • 產品核可的複雜監理要求

波特五力：駕馭集群性頭痛市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解叢集性頭痛市場的外部影響

外部宏觀環境因素在塑造叢集性頭痛市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解叢集性頭痛市場的競爭格局

對叢集性頭痛市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：集群頭痛市場供應商績效評估

FPNV定位矩陣是評估集群頭痛市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製叢集性頭痛市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對叢集性頭痛市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析最近的產品發布、開拓的地區、關鍵產業進展以及塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1. 目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3. 塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 哪些收益來源和策略機會推動供應商的進入/退出策略？

目錄

第1章簡介

第2章 分析方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球叢集性頭痛盛行率增加
      • 持續致力於藥品和醫療技術的研究和開發
      • 醫療投入快速增加，擴大治療選擇
    • 抑制因素
      • 對叢集性頭痛缺乏認知或誤診
    • 機會
      • 針對每位患者基因量身定做的個人化醫療的進展
      • 新開發的叢集性頭痛藥物的產品核可正在進行中
    • 任務
      • 產品核可的複雜監理要求
  • 市場區隔分析
    • 叢集性頭痛的類型：叢集性頭痛增加了治療慢性頭痛的藥物需求
    • 分銷管道：網路藥局越來越受到有效產品滲透的青睞
  • 波特五力分析
  • PESTEL分析
    • 政治因素
    • 經濟因素
    • 社會因素
    • 技術因素
    • 法律因素
    • 環境因素

第6章 叢集性頭痛市場：按叢集性頭痛類型

  • 慢性叢集性頭痛
  • 陣發性叢集性頭痛

第7章叢集性頭痛市場：依藥物類型

  • 抗癲癇藥
  • 鈣離子通道阻斷劑
  • 皮質類固醇
  • 麥角
  • 碳酸鋰
  • 褪黑素
  • Sumatriptan

第8章叢集性頭痛市場：依給藥途徑

  • 靜脈
  • 口服
  • 局部的

第 9 章 叢集性頭痛市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美和南美叢集性頭痛市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太集群性頭痛市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲叢集性頭痛市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭情境分析
    • 安進透過策略收購 Horizo​​n Therapeutics 擴大治療產品組合
    • Tonics Pharmaceuticals 透過策略性收購擴大偏頭痛治療產品組合
    • FDA核准QULIPTA 用於治療慢性和陣發性偏頭痛
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • electroCore, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Lundbeck LLC
  • Lupin Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CA100284D080

The Cluster Headache Market was valued at USD 381.04 million in 2023, expected to reach USD 401.80 million in 2024, and is projected to grow at a CAGR of 5.71%, to USD 562.38 million by 2030.

Cluster headaches are a neurological disorder characterized by severe, recurring pain in one side of the head, often around the eye. The scope of research and market analysis on cluster headaches involves understanding the necessity of effective treatments, their application in medical practice, and their end-use scope, which primarily includes pharmaceutical companies, healthcare providers, and patients. The demand for treatment solutions is driven by the rising prevalence of the disorder and the debilitating impact on patient quality of life. Key factors influencing market growth include advancements in neurological research, increasing awareness, and improving healthcare infrastructure. Innovative treatments like non-invasive neurostimulation and novel pharmaceutical formulations present emerging opportunities, driven by ongoing clinical trials and regulatory approvals. However, challenges such as high costs of novel treatments, limited patient access in developing regions, and the complexity of accurately diagnosing this rare condition pose significant market barriers. To harness potential opportunities, stakeholders should focus on partnerships between biotech firms and research institutions to accelerate R&D, investing in public awareness campaigns, and expanding accessibility through generic drug development. A concentrated effort on personalized medicine and exploring the genetic predispositions associated with cluster headaches may also unlock unexplored market potentials. While innovation is currently directed towards targeted drug therapies and technological integration, a deeper exploration into non-pharmaceutical interventions, such as lifestyle modifications and integrative therapies, could diversify treatment pipelines. The competitive landscape remains moderately concentrated, with established pharmaceutical giants, like GlaxoSmithKline, vying against emerging biotech firms. Ultimately, the cluster headache market is poised for growth, driven by unmet clinical needs and evolving treatment paradigms, but overcoming economic and educational constraints remains crucial for achieving equitable market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 381.04 million
Estimated Year [2024] USD 401.80 million
Forecast Year [2030] USD 562.38 million
CAGR (%) 5.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cluster Headache Market

The Cluster Headache Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cluster headaches worldwide
    • Ongoing research and development initiatives in pharmaceuticals and medical technology
    • Surging healthcare investments to advance treatment options
  • Market Restraints
    • Low awareness or misdiagnosis of cluster headaches
  • Market Opportunities
    • Advancements in personalized medicines tailored to individual patient genetics
    • Ongoing product approvals for newly developed cluster headache drugs
  • Market Challenges
    • Complex regulatory requirements for product approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cluster Headache Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cluster Headache Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cluster Headache Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cluster Headache Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cluster Headache Market

A detailed market share analysis in the Cluster Headache Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cluster Headache Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cluster Headache Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cluster Headache Market

A strategic analysis of the Cluster Headache Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cluster Headache Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen, Inc., Boehringer Ingelheim International GmbH, electroCore, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Lundbeck LLC, Lupin Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cluster Headache Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cluster Headaches Type, market is studied across Chronic Cluster Headaches and Episodic Cluster Headaches.
  • Based on Drug Type, market is studied across Anti-Seizure Drugs, Calcium Channel Blockers, Corticosteroids, Ergots, Lithium carbonate, Melatonin, and Sumatriptan.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cluster headaches worldwide
      • 5.1.1.2. Ongoing research and development initiatives in pharmaceuticals and medical technology
      • 5.1.1.3. Surging healthcare investments to advance treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness or misdiagnosis of cluster headaches
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in personalized medicines tailored to individual patient genetics
      • 5.1.3.2. Ongoing product approvals for newly developed cluster headache drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory requirements for product approvals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cluster Headaches Type: Increasing need for drugs to treat chronic cluster headache
    • 5.2.2. Distribution Channel: Rising preference for online pharmacies for effective product penetration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cluster Headache Market, by Cluster Headaches Type

  • 6.1. Introduction
  • 6.2. Chronic Cluster Headaches
  • 6.3. Episodic Cluster Headaches

7. Cluster Headache Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Anti-Seizure Drugs
  • 7.3. Calcium Channel Blockers
  • 7.4. Corticosteroids
  • 7.5. Ergots
  • 7.6. Lithium carbonate
  • 7.7. Melatonin
  • 7.8. Sumatriptan

8. Cluster Headache Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Cluster Headache Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Cluster Headache Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cluster Headache Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cluster Headache Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Amgen Expands Therapeutic Portfolio Through Strategic Acquisition of Horizon Therapeutics
    • 13.3.2. Tonix Pharmaceuticals Expands Migraine Treatment Portfolio with Strategic Acquisition
    • 13.3.3. FDA Approval of QULIPTA for Treatment of Chronic and Episodic Migraine
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Biogen, Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. electroCore, Inc.
  • 7. Eli Lilly and Company
  • 8. GlaxoSmithKline PLC
  • 9. Lundbeck LLC
  • 10. Lupin Limited
  • 11. Pfizer Inc.
  • 12. Sun Pharmaceutical Industries Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CLUSTER HEADACHE MARKET RESEARCH PROCESS
  • FIGURE 2. CLUSTER HEADACHE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLUSTER HEADACHE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLUSTER HEADACHE MARKET DYNAMICS
  • TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CHRONIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EPISODIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-SEIZURE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023